The AIB1 polyglutamine repeat does not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers

Cancer Epidemiology Biomarkers and Prevention

Volumn 15, Issue 1, 2006, Pages 76-79

  Spurdle, Amanda B ^a,l   Antoniou, Antonis C ^b   Kelemen, Livia ^a   Holland, Helene ^a   Peock, Susan ^b   Cook, Margaret R ^b   Smith, Paula L ^b   Greene, Mark H ^c   Simard, Jacques ^d   Plourde, Marie ^d   Southey, Melissa C ^e   Godwin, Andrew K ^g   Beck, Jeanne ^h   Miron, Alexander ⁱ   Daly, Mary B ^g   Santella, Regina M ^f   Hopper, John L ^e   John, Esther M ^j   Andrulis, Irene L ^k   Durocher, Francine ^d   Struewing, Jeffery P ^c   Easton, Douglas F ^b   Chenevix Trench, Georgia ^a   more..

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c NATIONAL CANCER INSTITUTE   (United States)

^d LAVAL UNIVERSITY   (Canada)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f Columbia University ^*  (United States)

^g FOX CHASE CANCER CENTER   (United States)

^h Laboratory of Molecular and Cellular Biology of Hematopoiesis   (United States)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

^j NORTHERN CALIFORNIA CANCER CENTER   (United States)

^k MOUNT SINAI HOSPITAL   (Canada)

^l ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; BRCA1 PROTEIN; BRCA2 PROTEIN; CYTOSINE; GENE PRODUCT; GUANINE; POLYGLUTAMINE; STEROID HORMONE; ACYLTRANSFERASE; HISTONE ACETYLTRANSFERASE; NUCLEAR RECEPTOR COACTIVATOR 3; ONCOPROTEIN; PEPTIDE; TRANSACTIVATOR PROTEIN;

AIB1 GENE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE; GENE FUNCTION; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; NUCLEOTIDE REPEAT; PRIORITY JOURNAL; BREAST TUMOR; GENETIC PREDISPOSITION; GENETICS; MUTATION; PROPORTIONAL HAZARDS MODEL; RISK; TUMOR SUPPRESSOR GENE;

ACETYLTRANSFERASES; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HISTONE ACETYLTRANSFERASES; HUMANS; MUTATION; ONCOGENE PROTEINS; PEPTIDES; POLYMORPHISM, GENETIC; PROPORTIONAL HAZARDS MODELS; REPETITIVE SEQUENCES, NUCLEIC ACID; RISK; TRANS-ACTIVATORS;

EID: 33645449964     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-05-0709     Document Type: Article

References (19)

1. Anzick SL, Kononen J, Walker RL, et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997;277:965-8.
2. Bautista S, Valles H, Walker RL, et al. In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity. Clin Cancer Res 1998;4:2925-9.
3. List HJ, Reiter R, Singh B, Wellstein A, Riegel AT. Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue. Breast Cancer Res Treat 2001;68:21-8.
4. Glaeser M, Floetotto T, Hanstein B, Beckmann MW, Niederacher D. Gene amplification and expression of the steroid receptor coactivator SRC3 (AIB1) in sporadic breast and endometrial carcinomas. Horm Metab Res 2001;33:121-6.
5. Bouras T, Southey MC, Venter DJ. Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu. Cancer Res 2001;61:903-7.
6. Osborne CK, Bardou V, Hopp TA, et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003;95:353-61.
7. Dai P, Wong LJ. Somatic instability of the DNA sequences encoding the polymorphic polyglutamine tract of the AIB1 gene. J Med Genet 2003;40:885-90.
8. Rebbeck TR, Wang Y, Kantoff PW, et al. Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. Cancer Res 2001;61:5420-4.
9. Kadouri L, Kote-Jarai Z, Easton DF, et al. Polyglutamine repeat length in the AIB1 gene modifies breast cancer susceptibility in BRCA1 carriers. Int J Cancer 2004;108:399-403.
10. Hughes DJ, Ginolhac SM, Coupier I, et al. Breast cancer risk in BRCA1 and BRCA2 mutation carriers and polyglutamine repeat length in the AIB1 gene. Int J Cancer 2005;117:230-3.
11. Spurdle AB, Antoniou AC, Duffy DL, et al. The androgen receptor CAG repeat polymorphism and modification of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res 2005;7:R176-83.
12. John EM, Hopper JL, Beck JC, et al. The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res 2004;6:R375-89.
13. Wang WW, Spurdle AB, Kolachana P, et al. A single nucleotide polymorphism in the 5′ untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2001;10:955-60.
14. Struewing JP, Brody LC, Erdos MR, et al. Detection of eight BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer. Am J Hum Genet 1995;57:1-7.
15. Vezina H, Durocher F, Dumont M, et al. Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families. Hum Genet 2005;117:119-32.
16. Montgomery KG, Chang JH, Gertig DM, et al. The AIB1 glutamine repeat polymorphism is not associated with risk of breast cancer before age 40 years in Australian women. Breast Cancer Res 2005;7:R353-6.
17. Huber PJ. The behaviour of maximum likelihood estimates under non-standard conditions. In: Fifth Berkeley Symposium in Mathematical Statistics and Probability. Berkeley (CA): University of California Press; 1967. p. 221-33.
18. Antoniou AC, Goldgar DE, Andrieu N, et al. A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes. Genet Epidemiol 2005;29:1-11.
19. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-30.